Predicine

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.